Prof Steve Anderton | Chief Scientific Officer
Aquila BioMedical

Prof Steve Anderton, Chief Scientific Officer, Aquila BioMedical

Steve Anderton is Chief Scientific Officer for Aquila BioMedical, which is based at Edinburgh’s BioQuarter campus. He combines his Aquila role with his academic role as Professor of Therapeutic Immunology at the University of Edinburgh, where he leads a research theme at the MRC Centre for Inflammation Research. Steve is an internationally leading immunologist, with 100+ publications in the fields of T cell activation, T cell tolerance, Treg biology and immunotherapy in autoimmune and allergic diseases, and in cancer. This expertise has helped to build Aquila’s innovative platform of in vitro and in vivo assays to accelerate discovery in immuno-oncology.


WIC 2017 Day 1, Tuesday 31st October 2017 @ 16:50

Innovative solutions for immuno-oncology drug discovery

  • Bespoke immunoassays for target validation, mode-of-action studies and combination immunotherapy design
  • In vitro and in vivo tumour-killing and immune response profiling
  • Advanced multiplex histology for visualisation and co-localisation of targets

back to speakers